Fig. 3

Infiltration of tumors in the skin by CD3⁺ cells correlates with delay in allogeneic tumor rejection seen in FucTVII^−/− and FucTIV^−/−/VII^−/− mice. a Tumors from WT B6 mice showed mild-to-moderate CD3⁺ infiltrate as early as 3 days after tumor implantation. b Tumors from WT B6 mice showed robust infiltrate at 7 days. c Tumors from FucTVII^−/− B6 mice showed minimal infiltrate at 7 days. d Tumors from FucTVII^−/− B6 mice showed significant CD3⁺ infiltrate at 11 days, as tumors started to regress. e Tumors from double-knockout FucTIV^−/−/VII^−/− B6 mice showed minimal infiltrate at 15 days. f Tumors from double-knockout FucTIV^−/−/VII^−/−B6 mice showed significant CD3⁺ infiltrate at 19 days, as tumors started to shrink. g BALB/c showed minimal CD3⁺ infiltrate at 3 days. h BALB/c still showed minimal infiltrate at 19 days. Representative histopathology preparations are shown for each